Company
Novelty Nobility
Leadership
SAB
Contact Us
Platform
PREXISE-D
Pipeline
People
Culture
Careers
News
Careers
Publications
Blog
Terms of Use
Private Policy
ddd
Company
Novelty Nobility
Leadership
SAB
Contact Us
Platform
PREXISE-D
Pipeline
People
Culture
Careers
News
Careers
Publications
Blog
Terms of Use
Private Policy
PREXISE-D, Fit-for-Purpose
Antibody Design & Discovery
Learn more
Overcoming Drug Resistance
with Antibody-Drug Conjugate
Learn more
Bringing a Beautiful Moment of
Eye Contact to Everyone
Learn more
NEWS
[서울경제] 박상규 노벨티노빌리티 대표 “면역·염증질환서 승부…신약 3상까지 직접 개발”...
[아이알팜] 7443억 대형 L/O 터뜨린 노벨티노빌리티 박상규 대표 “2027년 코스닥 상장·면역염증 전문 바...
[바이오스펙테이터] 노벨티노벨리티, 'c-Kit ADC' 美바이오텍에 5.53억弗 L/O...
[팜뉴스] 노벨티노빌리티, 중기부 ‘신약 파이프라인 공동개발 과제’ 선정
[바이오타임즈] 노벨티노빌리티, ‘NN2802’ 중국 임상 1b/2상 승인